Free Trial
NASDAQ:NEUP

Neuphoria Therapeutics Q4 2026 Earnings Results & Report

Neuphoria Therapeutics logo
$3.32 -0.07 (-1.92%)
As of 12:47 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Neuphoria Therapeutics was expected to report Q4 2026 earnings on September 2, 2026, before market opens. Analysts expected earnings of -$0.56 per share. Confirmed results have not been posted yet. This page will update with the reported figures, conference call transcript, and earnings documents as they become available.

Earnings Announcement Details

Quarter
Q4 2026
Announcement Date
Time
Before Market Opens

Neuphoria Therapeutics EPS Results

Actual EPS
N/A
Consensus EPS
-$0.56
Beat/Miss
N/A
One Year Ago EPS
N/A
EPS Beat Rate
3 of last 6 quarters

Neuphoria Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Earnings Documents

Neuphoria Therapeutics Earnings Headlines

Neuphoria Therapeutics Inc Ordinary Shares NEUP
My next big call (under $1)
17,556% on KDA. Here's what I'm buying now. It's a coin under $1.00 that most investors have never heard of. But the world's largest bank is already building on it. It has a deflationary burn mechanism tied directly to institutional usage.tc pixel
Neuphoria Therapeutics Inc (NEUP)
See More Neuphoria Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Neuphoria Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Neuphoria Therapeutics and other key companies, straight to your email.

About Neuphoria Therapeutics

Neuphoria Therapeutics (NASDAQ:NEUP), Inc. is a clinical-stage biotechnology company focused on developing regenerative cell therapies for neurological disorders. The company’s programs are intended to address conditions in which existing treatments may be inadequate, including certain forms of epilepsy and other disorders affecting the central nervous system.

Its lead investigational program, NRTX-1001, is a neural cell therapy being developed for drug-resistant focal epilepsy. The treatment is designed to deliver specialized neural cells that may help restore or regulate disrupted brain activity. NRTX-1001 remains an investigational product and has not been established as safe or effective for commercial use.

Neuphoria’s development activities are centered on advancing its therapeutic pipeline through clinical research and regulatory processes. Publicly available information about the company’s broader operations, geographic reach and executive leadership is limited.

View Neuphoria Therapeutics Profile